{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:10Z","timestamp":1786994410657,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014351","name":"CinnaGen Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.msard.2024.105839","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T02:51:06Z","timestamp":1724381466000},"page":"105839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY)"],"prefix":"10.1016","volume":"90","author":[{"given":"Vahid","family":"Shaygannejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Saeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Beladi Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Ghalyanchi Langroodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Baghbanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Abolfazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Ghiasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormoz","family":"Ayromlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Asadollahzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Sabzvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-7114","authenticated-orcid":false,"given":"Amirreza","family":"Azimi Saeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105839_bib0001","unstructured":"https:\/\/www.meddra.org\/about-meddra\/evolving-meddra. (Accessed May 2023)."},{"issue":"8","key":"10.1016\/j.msard.2024.105839_bib0002","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1007\/s00415-017-8544-6","article-title":"Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study","volume":"264","author":"Arnold","year":"2017","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.105839_bib0003","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of beck depression inventories -IA and -II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J. Pers. Assess."},{"key":"10.1016\/j.msard.2024.105839_bib0004","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2024.105839_bib0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105839_bib0006","unstructured":"Centre, U.M., 2018. The use of the WHO-UMC system for standardised case causality assessment. https:\/\/who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf (Accessed May 2023)."},{"issue":"7","key":"10.1016\/j.msard.2024.105839_bib0007","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-021-00822-z","article-title":"Interferons and multiple sclerosis: lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex)","volume":"35","author":"Cohan","year":"2021","journal-title":"CNS. Drugs"},{"issue":"3","key":"10.1016\/j.msard.2024.105839_bib0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2019","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105839_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105839_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.msard.2024.105839_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105839_bib0012","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4103\/0028-3886.33316","article-title":"Validity and reliability of the Persian version of the multiple sclerosis quality of life questionnaire","volume":"55","author":"Ghaem","year":"2007","journal-title":"Neurol. India"},{"issue":"4","key":"10.1016\/j.msard.2024.105839_bib0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/da.20070","article-title":"Psychometric properties of a Persian-language version of the Beck Depression Inventory\u2013Second edition: BDI-II-PERSIAN","volume":"21","author":"Ghassemzadeh","year":"2005","journal-title":"Depress. Anxiety."},{"issue":"6","key":"10.1016\/j.msard.2024.105839_bib0014","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0091270011407068","article-title":"A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology","volume":"52","author":"Hu","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.msard.2024.105839_bib0015","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/1352458514557986","article-title":"Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE","volume":"21","author":"Kieseier","year":"2015","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2024.105839_bib0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/11596970-000000000-00000","article-title":"PEGylation of interferon-\u03b2-1a: a promising strategy in multiple sclerosis","volume":"26","author":"Kieseier","year":"2012","journal-title":"CNS. Drugs"},{"issue":"11","key":"10.1016\/j.msard.2024.105839_bib0017","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.105839_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211000461","article-title":"Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study","volume":"14","author":"Menge","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105839_bib0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1756285616676065","article-title":"Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE","volume":"10","author":"Newsome","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105839_bib0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/jir.2022.0238","article-title":"Prolonged interferon-stimulated gene and protein signatures in multiple sclerosis induced by PEGylated IFN-\u03b2-1a Compared to Non-PEGylated IFN-\u03b2-1a","volume":"43","author":"Nguyen","year":"2023","journal-title":"J. Interferon. Cytokine Res."},{"issue":"27","key":"10.1016\/j.msard.2024.105839_bib0021","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.2174\/0929867325666180226105612","article-title":"New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis","volume":"25","author":"Ortiz","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.msard.2024.105839_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2024.105839_bib0023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756285613484079","article-title":"Magnetic resonance monitoring of lesion evolution in multiple sclerosis","volume":"6","author":"Rovira","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2024.105839_bib0024","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00281-019-00765-0","article-title":"Resolution of inflammation during multiple sclerosis","volume":"41","author":"Ruiz","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"12","key":"10.1016\/j.msard.2024.105839_bib0025","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3174\/ajnr.A5773","article-title":"Gadolinium and multiple sclerosis: vessels, barriers of the brain, and glymphatics","volume":"39","author":"Saade","year":"2018","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.msard.2024.105839_bib0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.nic.2017.01.002","article-title":"Brain atrophy in multiple sclerosis: clinical relevance and technical aspects","volume":"27","author":"Sastre-Garriga","year":"2017","journal-title":"NeuroimAging Clin. N. Am."},{"key":"10.1016\/j.msard.2024.105839_bib0027","article-title":"Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis","volume":"2","author":"Scott","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2024.105839_bib0028","unstructured":"Services, U.S.D.O.H.A.H., 2017. Common terminology criteria for adverse events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5\u00d77.pdf. (Accessed May 2023)."},{"issue":"6","key":"10.1016\/j.msard.2024.105839_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127960","article-title":"A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis","volume":"10","author":"Tolley","year":"2015","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.msard.2024.105839_bib0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ana.10147","article-title":"Age-related disability in multiple sclerosis","volume":"51","author":"Trojano","year":"2002","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.105839_bib0031","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1212\/WNL.47.6.1469","article-title":"Accumulation of hypointense lesions (\"black holes\") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis","volume":"47","author":"Truyen","year":"1996","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.105839_bib0032","unstructured":"Use, I.C.o.H.o.T.R.f.R.o.P.f.H., 2001. maintenance of the ICH guideline on clinical safety data management: Data elements for transmission of individual case safety reports E2B(R2), . https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/E2B_R2_Guideline.pdf (Accessed May 2023)."},{"issue":"5","key":"10.1016\/j.msard.2024.105839_bib0033","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/WNL.50.5.1282","article-title":"Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis","volume":"50","author":"van Walderveen","year":"1998","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2024.105839_bib0034","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual. Life Res."},{"issue":"14","key":"10.1016\/j.msard.2024.105839_bib0035","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105839_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105839_bib0037","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1212\/CPJ.0000000000001177","article-title":"Predictors of disease activity and worsening in relapsing-remitting multiple sclerosis","volume":"12","author":"Zhang","year":"2022","journal-title":"Neurol. Clin. Pract."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T03:57:05Z","timestamp":1726372625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824004164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"alternative-id":["S2211034824004164"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105839","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY)","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105839"}}